Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) - Total Liabilities
Based on the latest financial reports, Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has total liabilities worth CN¥2.56 Billion CNY (≈ $374.76 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Tianjin Zhongxin Pharmaceutical Group Co long-term investment intensity to see how much of total assets are deployed in long-term investments.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Total Liabilities Trend (1998–2024)
This chart illustrates how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Tianjin Zhongxin Pharmaceutical Group Co total assets.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Plug Power Inc
NASDAQ:PLUG
|
USA | $1.61 Billion |
|
SPS Commerce Inc
NASDAQ:SPSC
|
USA | $186.95 Million |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
China | CN¥13.21 Billion |
|
Fujian Newland Computer Co Ltd
SHE:000997
|
China | CN¥7.76 Billion |
|
SpareBank 1 Østlandet
OL:SPOL
|
Norway | Nkr186.90 Billion |
|
ABM Industries Incorporated
NYSE:ABM
|
USA | $3.81 Billion |
|
Himadri Speciality Chemical Limited
NSE:HSCL
|
India | Rs-47.62 Billion |
|
Immunome Inc
NASDAQ:IMNM
|
USA | $40.30 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down Tianjin Zhongxin Pharmaceutical Group Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Tianjin Zhongxin Pharmaceutical Group Co (600329) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (1998–2024)
The table below shows the annual total liabilities of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.92 Billion ≈ $427.10 Million |
-18.58% |
| 2023-12-31 | CN¥3.58 Billion ≈ $524.58 Million |
-0.56% |
| 2022-12-31 | CN¥3.61 Billion ≈ $527.53 Million |
+41.19% |
| 2021-12-31 | CN¥2.55 Billion ≈ $373.62 Million |
+9.42% |
| 2020-12-31 | CN¥2.33 Billion ≈ $341.46 Million |
+0.58% |
| 2019-12-31 | CN¥2.32 Billion ≈ $339.48 Million |
+13.12% |
| 2018-12-31 | CN¥2.05 Billion ≈ $300.11 Million |
+2.73% |
| 2017-12-31 | CN¥2.00 Billion ≈ $292.12 Million |
-3.02% |
| 2016-12-31 | CN¥2.06 Billion ≈ $301.21 Million |
+4.82% |
| 2015-12-31 | CN¥1.96 Billion ≈ $287.35 Million |
-21.15% |
| 2014-12-31 | CN¥2.49 Billion ≈ $364.45 Million |
-7.32% |
| 2013-12-31 | CN¥2.69 Billion ≈ $393.25 Million |
+25.48% |
| 2012-12-31 | CN¥2.14 Billion ≈ $313.40 Million |
+10.48% |
| 2011-12-31 | CN¥1.94 Billion ≈ $283.67 Million |
+10.80% |
| 2010-12-31 | CN¥1.75 Billion ≈ $256.02 Million |
-6.88% |
| 2009-12-31 | CN¥1.88 Billion ≈ $274.94 Million |
-4.73% |
| 2008-12-31 | CN¥1.97 Billion ≈ $288.60 Million |
-7.27% |
| 2007-12-31 | CN¥2.13 Billion ≈ $311.21 Million |
+1.36% |
| 2006-12-31 | CN¥2.10 Billion ≈ $307.05 Million |
-0.41% |
| 2005-12-31 | CN¥2.11 Billion ≈ $308.31 Million |
+3.50% |
| 2004-12-31 | CN¥2.04 Billion ≈ $297.89 Million |
+3.95% |
| 2003-12-31 | CN¥1.96 Billion ≈ $286.56 Million |
+48.48% |
| 2002-12-31 | CN¥1.32 Billion ≈ $192.99 Million |
+11.91% |
| 2001-12-31 | CN¥1.18 Billion ≈ $172.46 Million |
-14.37% |
| 2000-12-31 | CN¥1.38 Billion ≈ $201.39 Million |
+348.34% |
| 1999-12-31 | CN¥306.96 Million ≈ $44.92 Million |
+39.19% |
| 1998-12-31 | CN¥220.53 Million ≈ $32.27 Million |
-- |
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more